Találati lista | Tudóstér

001-es BibID:	BIBFORM013921
Első szerző:	Soltész Pál (belgyógyász, kardiológus)
Cím:	Comparative assessment of vascular function in autoimmune rheumatic diseases : consideration of prevention and treatment / Soltész Pál, Kerekes György, Dér Henrietta, Szűcs Gabriella, Szántó Sándor, Kiss Emese, Bodolay Edit, Zeher Margit, Tímár Orsolya, Szodoray Péter, Szegedi Gyula, Szekanecz Zoltán
Dátum:	2011
ISSN:	1568-9972
Megjegyzések:	Numerous autoimmune-inflammatory rheumatic diseases have been associated with accelerated atherosclerosis or other types of vasculopathy leading to increased cardio- and cerebrovascular disease risk. Traditional risk factors, as well as the role of systemic inflammation including cytokines, chemokines, proteases, autoantibodies, adhesion receptors and others have been implicated in the development of these vascular pathologies. The characteristics of vasculopathies may significantly differ depending on the underlying disease. While classical accelerated atherosclerosis has been associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or spondyloarthropathies (SpA), obliterative vasculopathy may rather be characteristic for systemic sclerosis (SSc) or mixed connective tissue disease (MCTD). Antiphospholipid antibodies have been implicated in vasculopathies underlying SLE, antiphospholipid syndrome (APS), RA and MCTD. There is also heterogeneity with respect to inflammatory risk factors. Cytokines, such as tumor necrosis factor-alpha (TNF-alpha) or interleukin 6 (IL-6) and immune complexes are primarily involved in arthritides, such as RA, SpA, as well as in SLE. On the other hand, autoantibodies including anti-oxLDL anti-cardiolipin and anti-beta2GPI are rather involved in SLE- and APS-associated vasculopathies. Regarding the non-invasive assessment of vascular function, endothelial dysfunction, overt atherosclerosis and vascular stiffness may be indicated by brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT) and aortic pulse-wave velocity (PWV), respectively. These abnormalities have been described in most inflammatory rheumatic diseases. While ccIMT and stiffness are relatively stable, FMD may be influenced by many confounding factors. In addition to traditional vasculoprotection, immunosuppressive agents including corticosteroids, traditional and biologic DMARDs may have significant vascular and metabolic effects. The official EULAR recommendations on the assessment and management of cardiovascular disease in arthritides have just been published, and similar recommendations in connective tissue diseases are to be developed soon.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	Autoimmunity Reviews. - 10 : 7 (2011), p. 416-425. -
További szerzők:	Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Dér Henrietta (1977-) (orvos) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Kiss Emese (1960-) (belgyógyász, immunológus) Bodolay Edit (1950-) (belgyógyász, allergológus és klinikai immunológus) Zeher Margit (1957-2018) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Tímár Orsolya (1980-) (belgyógyász) Szodoray Péter (1973-) (belgyógyász, orvos) Szegedi Gyula (1936-2013) (belgyógyász, immunológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI elektronikus változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM015790
Első szerző:	Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:	Biologics - beyond the joints? / Zoltán Szekanecz, Sándor Szántó, Zoltán Szabó, Andrea Váncsa, Szilvia Szamosi, Nóra Bodnár, Gabriella Szücs
Dátum:	2010
ISSN:	1568-9972
Megjegyzések:	Biologics including tumor necrosis factor alpha (TNF-alpha), interleukin-6 receptor (IL-6R), T and B cell inhibitors are very effective therapeutic agents for the treatment of arthritides. These compounds effectively improve articular symptoms and inhibit joint damage. In this respect, there are no major differences in the efficacy of the available biologics. However, many arthritis patients also exert extra-articular features, systemic manifestations of the disease. These associated conditions include uveitis, inflammatory bowel disease, psoriasis, secondary bone loss and cardiovascular disease. There have been data suggesting that there may be differences in the effects of various TNF inhibitors, rituximab and tocilizumab on the systemic manifestations described above. At present, we do not always have sufficient evidence to confirm these differences, therefore, more information should be obtained from large trials and long-term observational studies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Autoimmunity Reviews. - 9 : 12 (2010), p. 820-824. -
További szerzők:	Szántó Sándor (1968-) (belgyógyász, reumatológus) Szabó Zoltán (1970-) (belgyógyász, reumatológus) Váncsa Andrea (1972-) (orvos) Szamosi Szilvia (1975-) (belgyógyász, reumatológus) Bodnár Nóra (1980-) (reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM067625
Első szerző:	Szentpétery Ágnes (reumatológus)
Cím:	Effects of targeted therapies on the bone in arthritides / Ágnes Szentpétery, Ágnes Horváth, Katalin Gulyás, Zsófia Pethö, Harjit Pal Bhattoa, Sándor Szántó, Gabriella Szücs, Oliver FitzGerald, Georg Schett, Zoltán Szekanecz
Dátum:	2017
ISSN:	1568-9972
Megjegyzések:	Inflammatory arthritides, such as rheumatoid arthritis (RA) and spondyloarthritides (SpA) have been associated with both localized bone resorption and/or formation, and generalized osteoporosis. Systemic inflammation may be the major driver for bone loss in arthritis. In RA and peripheral SpA the RANK-RANKL-OPG network is involved in bone resorption, while in axial SpA the Wnt-?-catenin axis and its inhibitors (DKK-1, sclerostin) are the most relevant. Targeted therapies including biologics and small molecule tyrosine kinase inhibitors may interfere with inflammatory bone metabolism. Most of these compounds are able to slow down radiographic progression and osteoporosis in arthritides. In very early cases of non-radiological SpA, there may be a window of opportunity allowing to prevent syndesmophyte formation. The inability of targeted therapies to increase the production of DKK-1 and sclerostin may explain the lack of efficacy of TNF inhibitors to halt syndesmophyte formation in SpA. Further clinical trials are needed to better understand the bone effects of targeted therapies.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Biologics Bone loss DKK-1 Erosion JAK inhibitors Osteoporosis Osteoprotegerin RANKL Rheumatoid arthritis Sclerostin Spondyloarthritis Syndesmophyte
Megjelenés:	Autoimmunity Reviews 16 : 3 (2017), p. 313-320. -
További szerzők:	Horváth Ágnes (1985-) (reumatológus) Gulyás Katalin (reumatológus) Pethő Zsófia (1981-) (reumatológus, immunológus) Bhattoa Harjit Pal (1973-) (laboratóriumi szakorvos) Szántó Sándor (1968-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) FitzGerald, Oliver Schett, Georg Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:	K 105073 OTKA TÁMOP-4.2.4.A/2-11-1-2012-0001 TÁMOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM007140
Első szerző:	Szodoray Péter (belgyógyász, orvos)
Cím:	Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis / Szodoray, P., Szabo, Z., Kapitany, A., Gyetvai, A., Lakos, G., Szanto, S., Szucs, G., Szekanecz, Z.
Dátum:	2010
ISSN:	1873-0183 (Electronic)
Megjegyzések:	Anti-citrullinated protein/peptide antibodies (ACPA) have recently emerged as sensitive and specific serological markers of rheumatoid arthritis (RA), providing superior alternative of the rheumatoid factor (RF) test in the laboratory diagnostics of RA. Citrullination is a post-translational modification of arginine by deimination, physiologically occurring during apoptosis, inflammation or keratinization. The presence of several citrullinated proteins has been demonstrated in the RA synovium. The identification of citrullinated epitopes as targets led to the development of the first and later second-generation anti-cyclic citrullinated peptide (anti-CCP) antibody assays. The anti-Sa antibody has been identified a decade ago; however, recent studies confirmed that anti-Sa is directed against citrullinated vimentin. The determination of ACPA may have important prognostic significance, since ACPA production can precede the onset of clinical RA symptoms by years. ACPA(+) individuals with early, undifferentiated arthritis may have higher risk to develop RA. ACPA has important prognostic role during the progression of RA and it has also been associated with pronounced radiographic progression. ACPA production has been associated with several genetic predisposing factors, including HLA-DRB1 and PTPN22 1858T alleles, as well as with environmental and lifestyle-related factors, primarily smoking and possibly, the use of oral contraceptives and excessive caffeine intake. Thus, the assessment of ACPA, in addition to clinical, radiographic and genetic outcome measures may be important to assess disease prognosis and aids to design effective, early therapeutic strategies.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Animals Arthritis, Rheumatoid/diagnosis/genetics/immunology/therapy Autoantibodies/blood/immunology Citrulline/immunology Genetic Testing Humans Peptides/immunology Prognosis
Megjelenés:	Autoimmunity Reviews. - 9 : 3 (2010), p. 140-143. -
További szerzők:	Szabó Zoltán (1970-) (belgyógyász, reumatológus) Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Lakos Gabriella (1963-) (laboratóriumi szakorvos, transzfúziológus, immunológus) Szántó Sándor (1968-) (belgyógyász, reumatológus) Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon: